Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Up 107.0% in June

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,245 shares, an increase of 107.0% from the June 15th total of 1,568 shares. Based on an average daily trading volume, of 59,123 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Institutional Trading of Xtant Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Wiregrass Investment Management LLC bought a new position in shares of Xtant Medical during the fourth quarter valued at approximately $81,000. Renaissance Technologies LLC lifted its holdings in shares of Xtant Medical by 28.8% in the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares during the last quarter. Vanguard Group Inc. boosted its position in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares during the period. Nantahala Capital Management LLC boosted its position in Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after purchasing an additional 57,000,000 shares during the period. Finally, Tradition Wealth Management LLC bought a new position in Xtant Medical during the 4th quarter worth $79,000. 69.33% of the stock is owned by institutional investors and hedge funds.

Xtant Medical Stock Down 2.6%

XTNT traded down $0.01 during trading hours on Wednesday, reaching $0.45. 113,518 shares of the stock traded hands, compared to its average volume of 147,096. The firm’s fifty day simple moving average is $0.45 and its two-hundred day simple moving average is $0.55. The company has a market cap of $62.67 million, a price-to-earnings ratio of 44.72 and a beta of -0.16. Xtant Medical has a fifty-two week low of $0.39 and a fifty-two week high of $0.95. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.34 and a quick ratio of 1.64.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings results on Wednesday, May 13th. The medical device company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). The firm had revenue of $20.88 million during the quarter, compared to the consensus estimate of $20.16 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on XTNT. Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. BTIG Research restated a “buy” rating and set a $1.00 price target on shares of Xtant Medical in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $1.00.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.